Outlook Therapeutics
OTLK
12 hedge funds and large institutions have $2.15M invested in Outlook Therapeutics in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.01% less ownership
Funds ownership: 0.04% → 0.03% (-0.01%)
58% less capital invested
Capital invested by funds: $5.09M → $2.15M (-$2.93M)
88% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$18.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$437K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$141K |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$48K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$31.6K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $1.39M | -$437K | -3,553 | -17% |
|
|
ACA
2
Avoro Capital Advisors
New York
| $340K | -$2.71K | -22 | -0.5% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $194K | -$141K | -1,150 | -32% |
|
|
MWNA
4
Marshall Wace North America
New York
| $100K | -$48K | -390 | -24% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $57K | -$31.6K | -257 | -27% |
|
|
PAM
6
Panagora Asset Management
Boston,
Massachusetts
| $30K | +$18.2K | +148 | +64% |
|
|
ACP
7
Acuta Capital Partners
Redwood City,
California
| $15K | – | – | – |
|
|
MFGP
8
Marshall Financial Group (Pennsylvania)
Doylestown,
Pennsylvania
| $8K | +$11.6K | +94 | New |
|
9
Morgan Stanley
New York
| $5K | -$4.8K | -39 | -39% |
|
10
Bank of America
Charlotte,
North Carolina
| $5K | -$1.72K | -14 | -18% |
|
11
Geode Capital Management
Boston,
Massachusetts
| $5K | – | – | – |
|
12
UBS Group
Zurich,
Switzerland
| $1K | -$5.17K | -42 | -82% |
|
|
TSS
13
Two Sigma Securities
New York
| – | -$18K | -115 | Closed |
|
OTLK Hedge Fund Activity: Q4 2018 in Review
12 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2018, worth a combined $2.15M — down 58% from $5.09M a quarter earlier.
Fund positioning in OTLK was balanced in Q4 2018: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 8 trimmed.
The largest buyer was Panagora Asset Management, adding an estimated $18.2K. The largest seller was Sabby Management, cutting an estimated $437K.
- 12 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $2.15M of Outlook Therapeutics stock for Q4 2018, down 58% quarter-over-quarter.
- 1 fund opened new Outlook Therapeutics positions in Q4 2018 and 1 closed out, a net change of 0 holders.
- The largest Outlook Therapeutics buyer in Q4 2018 was Panagora Asset Management, an estimated $18.2K added.
- The largest Outlook Therapeutics seller in Q4 2018 was Sabby Management, an estimated $437K sold.
Based on aggregated 13F filings for Q4 2018.